Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma

Maria Debora De Pasquale, Rosanna Pessolano, Renata Boldrini, Ilaria Ilari, Alberto Donfrancesco, Enrico Cortesi, Alessandro Jenkner

Research output: Contribution to journalArticlepeer-review

Abstract

A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
Volume33
Issue number5
DOIs
Publication statusPublished - Jul 2011

Keywords

  • childhood
  • Renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this